Bremelanotide · MC4R Agonist · Protocol Guide
PT-141: The Unvarnished Guide You Have Been Looking For
Honest clinical data on PT-141 (bremelanotide), physician-supervised. What this peptide actually does for sexual dysfunction, what it costs, the 40 percent nausea rate, and what the research does not yet support.
FDA Status
FDA-Approved as Vyleesi (2019)
Pharmacy
Optimal Balance Pharmacy (503A licensed)
Medical Service
RxPepsDirect, physician-supervised
Access
33 U.S. States
Our promise: What this guide will not do: overstate efficacy, understate side-effect rates, or omit the clinical trial numbers that do not flatter this compound. The 40 percent nausea incidence from the RECONNECT Phase 3 trial is in here. So is the male evidence gap.
Medically reviewed by Dr. Jonathan Snipes, MD. Last reviewed May 18, 2026.Section 01
What PT-141 Actually Is
2019
FDA Approval Year (Vyleesi)
~2.7 hr
Plasma half-life
40%
Nausea incidence at fixed 1.75 mg dose, Phase 3
PT-141 (bremelanotide) is a synthetic melanocortin receptor agonist. It is not a vasodilator like Viagra or Cialis. It works through an entirely different mechanism: activating melanocortin-4 receptors (MC4R) in the central nervous system to trigger sexual arousal pathways at the brain level, rather than producing genital vasodilation peripherally.
The branded version, Vyleesi, received FDA approval in June 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women. It was the first FDA-approved on-demand treatment for low sexual desire. Every other application of bremelanotide is off-label.
Section 02
Who It Is Actually For
| Population | Description | Status |
|---|---|---|
| FDA-Approved | Premenopausal women with acquired, generalized HSDD, clinically diagnosed | Approved Indication |
| Off-Label (Women) | Situational HSDD, post-menopausal, secondary to SSRI use, post-cancer | Supported Off-Label |
| Off-Label (Men) | Psychogenic ED, desire-phase dysfunction, adjunct to PDE5 inhibitors | Limited Evidence |
| Not Indicated | Vasculogenic ED, hormonal hypogonadism, relationship-primary issues | Not Appropriate |
Population
Description
Status
Population
Description
Status
Population
Description
Status
Population
Description
Status
Section 03
How It Works
Bremelanotide binds to melanocortin-3 and melanocortin-4 receptors (MC3R and MC4R) in the central nervous system, particularly in the hypothalamus. MC4R activation triggers downstream neural signaling associated with sexual arousal, desire, and motivation. The pathway is mediated by dopaminergic, oxytocinergic, and noradrenergic systems converging on the medial preoptic area.
Because the mechanism is central rather than peripheral, PT-141 does not require intact penile vascular function to produce arousal. It also does not bypass the need for psychological engagement or neural signal integrity. Patients with intact central arousal capacity but suppressed desire are the highest- fit candidates.
Section 04
Realistic Expectations
PT-141 is on-demand. Onset is roughly 45 minutes after subcutaneous injection. Peak effect is at 2 to 4 hours. Duration of arousal effect ranges from 6 to 24 hours depending on individual response. This is not a daily medication. It is used anticipating sexual activity.
Injection to Initial Onset
Subcutaneous injection produces an initial neural signal roughly 15 minutes after administration. Most patients do not feel anything subjectively at this stage.
Onset of Effect
The window most patients report onset of central arousal effect. Some report flushing or warmth alongside the arousal signal. This is also when nausea, if it occurs, is most likely to appear.
Peak Effect
Peak central arousal effect. The window most patients aim to align with sexual activity. Plasma half-life is roughly 2.7 hours.
Tail of Effect
Some patients report lingering arousal sensitivity well beyond the peak. Reports vary widely. Do not redose during this tail period without physician guidance because of tachyphylaxis risk.
Section 05
Dosing Protocol
The branded Vyleesi autoinjector delivers a fixed 1.75 mg dose. Compounded bremelanotide filled by Optimal Balance Pharmacy against a RxPepsDirect prescription is dose-adjustable. The titration-up protocol below is the most common RxPepsDirect recommendation. It exists specifically to reduce the 40 percent nausea signal from the fixed-dose branded form.
| Step | Dose | Use Case | Evidence Basis |
|---|---|---|---|
| Titration Start | 500 mcg | First-ever PT-141 dose. Allows tolerance assessment and reduces nausea risk. | RxPepsDirect Protocol |
| Standard Effective Dose | 1.0 to 1.75 mg | Patients who tolerated the 500 mcg titration and need a stronger arousal signal. | Vyleesi Phase 3 Dose |
| Vyleesi Fixed Dose | 1.75 mg | The FDA-approved branded autoinjector dose. Same compound, no titration option. | Phase 3 RCT |
| Community Higher Dose | 2 mg or greater | No clinical basis above 1.75 mg. Increases side effect risk without proportional benefit. | No Clinical Basis |
Step
Dose
Use Case
Evidence Basis
Step
Dose
Use Case
Evidence Basis
Step
Dose
Use Case
Evidence Basis
Step
Dose
Use Case
Evidence Basis
Timing: Inject subcutaneously 45 minutes before anticipated sexual activity. The arousal effect peaks at 2 to 4 hours. Do not use more than once per 24 hours. Maximum 8 doses per month to limit tachyphylaxis.
Injection site: Subcutaneous into abdominal fat or thigh. Standard insulin syringe (28 to 31 gauge, 6 to 8 mm needle length).
Section 06
Side Effects: The Nausea Reality
The most discussed side effect of PT-141 is nausea. In the Phase 3 RECONNECT trials at the fixed 1.75 mg branded dose, roughly 40 percent of participants reported nausea. The signal is real. Compounded titration starting at 500 mcg reduces the incidence and severity, but it does not eliminate it.
| Side Effect | Incidence (Phase 3) | Management |
|---|---|---|
| Nausea | Roughly 40 percent at 1.75 mg | Start at 500 mcg, inject 2+ hours before food, consider ondansetron 4 mg ODT 30 min before injection. |
| Flushing | Roughly 20 percent | Usually transient. Resolves within 60 to 90 minutes. |
| Headache | Roughly 11 percent | Usually transient. Acetaminophen as needed. |
| Transient BP elevation | Roughly 7 percent | Contraindicated in uncontrolled hypertension or significant cardiovascular disease. Baseline BP check at intake. |
| Focal hyperpigmentation | Roughly 1 percent | Less common with intermittent dosing. Monitor for new pigmented lesions. |
Side Effect
Incidence (Phase 3)
Management
Side Effect
Incidence (Phase 3)
Management
Side Effect
Incidence (Phase 3)
Management
Side Effect
Incidence (Phase 3)
Management
Side Effect
Incidence (Phase 3)
Management
Section 07
Ready to Inject
0
Reconstitution steps required
503A
Licensed pharmacy (Optimal Balance), physician-supervised
Overnight
FedEx shipping in a reusable cooled travel case
Refrigerate immediately. Do not freeze. Use within the Beyond Use Date printed on the label, per USP <797> sterile compounding standards.
Section 08
Tachyphylaxis & Rest Periods
MC4R receptors downregulate with repeated stimulation. This is tachyphylaxis: rapid loss of sensitivity to the same dose. With PT-141, tachyphylaxis is the single biggest reason patients report that "the dose stopped working." It is not a sourcing problem and it is not a quality problem. It is receptor biology.
| Pattern | Risk | Mitigation |
|---|---|---|
| Once weekly or less | Low | No specific mitigation required. Receptor sensitivity preserved. |
| 2 to 3 times per week | Moderate | Insert at least 72 hours between doses. Consider one week off monthly. |
| Daily or near-daily | High | Reduce frequency immediately. Tachyphylaxis is likely. Dose escalation is not the answer. |
Pattern
Risk
Mitigation
Pattern
Risk
Mitigation
Pattern
Risk
Mitigation
"I made the mistake of using it back to back over a weekend trying to chase the first effect. By Monday it had basically stopped working. Took two weeks off and the next dose felt like the first one again."
Section 09
Stacking & Combinations
PT-141 pairs reasonably with PDE5 inhibitors and oxytocin (intranasal). It does not stack well with vasoactive compounds in patients with cardiovascular risk.
Pairs Well With
PDE5 inhibitors (sildenafil, tadalafil)
Different mechanism (peripheral vasodilation). Useful in men with desire-phase plus mild vascular component. Physician oversight required because both can lower BP.
Oxytocin (intranasal)
Different mechanism, complementary pathway. Some clinicians pair these for bonding-plus-arousal protocols.
Kisspeptin-10
Upstream of GnRH. Theoretical complementary effect on desire pathway. Limited combined data.
Approach With Caution
Uncontrolled hypertension
PT-141 produces transient BP elevation. Contraindicated until BP is controlled.
Nitrate medications
Severe BP-lowering risk when combined with vasoactive compounds. Physician evaluation required.
Recent cardiovascular event
BP elevation in the post-injection window is not safe in patients with recent MI or unstable angina.
Heavy alcohol
Increases nausea risk substantially. Avoid alcohol within 4 hours of injection.
Section 10
Pricing
| Option | Medication Cost | Medical Cost | Notes |
|---|---|---|---|
| Vyleesi (branded autoinjector) | $700 to $900 per 4 injections | Insurance and prescriber dependent | Fixed 1.75 mg dose. No titration. FDA-approved for HSDD in premenopausal women. |
| Other Online Clinics | $150 to $250 per vial | Visit fees often bundled and not disclosed publicly | Per-vial pricing varies. Verify all-in cost before committing. |
| Optimal Balance Pharmacy + RxPepsDirect | $75 per 10 mg vial, paid to pharmacy | $39 visit fee, paid to RxPepsDirect | Pre-reconstituted, dose-titratable, FedEx overnight, labeled to you. |
Option
Medication Cost
Medical Cost
Notes
Option
Medication Cost
Medical Cost
Notes
Option
Medication Cost
Medical Cost
Notes
Who You Pay, and What For
Pharmacy: Medication
$75 per 10 mg vial. Compounded and shipped by Optimal Balance Pharmacy, a 503A licensed compounding pharmacy. Pre-reconstituted, dose-titratable, FedEx overnight in a reusable cooled travel case.
Medical Service: Physician Consultation
$39 medical visit fee. Intake consultation including BP screening, protocol design with starting titration dose, prescription writing, and follow-up check-ins. Billed by RxPepsDirect for the medical service only.
Section 11
Legal Access in 33 States
FDA-Approved Finished Form
Vyleesi, AMAG Pharmaceuticals, 2019
503A Compounded Available
Patient-specific prescription required
Off-Label, Legal Practice
Standard and legal in U.S. medicine
Not Controlled, Not on Category 2
No DEA scheduling. Compoundable through 503A.
Bremelanotide has an FDA-approved finished form (Vyleesi) for hypoactive sexual desire disorder in premenopausal women. The compound is not a controlled substance and is not on the FDA Category 2 bulk drug substances list. Compounded bremelanotide remains available through 503A patient-specific compounding under physician prescription.
Off-label prescribing is a standard, legal practice in U.S. medicine. Your prescribing physician will explain the regulatory status and evidence base during your consultation.
Section 12
Community Q&A
Will PT-141 give me an erection on demand?
No. PT-141 is not a vasodilator. It acts on central arousal and desire pathways in the brain. If you have intact central arousal capacity but suppressed desire, it may help. If your dysfunction is vascular, a PDE5 inhibitor is the right tool. PT-141 layered onto a PDE5 inhibitor is an option your physician can evaluate.
How do I avoid the nausea?
Start at the 500 mcg titration dose, not the full Vyleesi 1.75 mg. Inject 2 or more hours after your last meal. Ondansetron 4 mg ODT 30 minutes before injection helps meaningfully. Avoid alcohol within 4 hours. These four steps reduce the Phase 3 nausea signal substantially.
The first dose worked great. The second did not. Why?
Tachyphylaxis. MC4R receptors downregulate quickly with repeated stimulation. The fix is not a higher dose. The fix is more time between doses. 72 hours minimum between uses, and one week off per month. If response continues to decline, take a two-week pause to restore receptor sensitivity.
Can I use Vyleesi for off-label indications?
Vyleesi is the FDA-approved finished form at fixed 1.75 mg dose. Off-label prescribing of an approved product is legal but ergonomically harder than compounded bremelanotide because there is no dose titration option. Most clinicians prescribing PT-141 outside the FDA-approved indication choose compounded bremelanotide for that reason.
What if I have high blood pressure?
PT-141 produces transient BP elevation. Uncontrolled hypertension is a contraindication until your BP is managed. Your RxPepsDirect intake includes a BP screening question. If your BP is borderline, your physician may ask you to obtain a recent reading from your primary care provider before prescribing.
Can women use the men's protocol and vice versa?
The compound and starting dose are the same. The FDA indication is for premenopausal women with HSDD. Men use PT-141 off-label for desire-phase dysfunction with limited Phase 3 data supporting efficacy. Both populations benefit from the 500 mcg titration start.
What happens if Optimal Balance Pharmacy is out of stock?
Pharmacy supply chains can fluctuate. If Optimal Balance is temporarily unable to fill your prescription, your RxPepsDirect physician will be notified and you will be contacted before any delay impacts your protocol. You only pay the pharmacy when your prescription actually ships.
Section 13
The RxPepsDirect Model
PT-141 is the only FDA-approved on-demand medication for hypoactive sexual desire disorder. Its mechanism is genuinely different from PDE5 inhibitors, and for the right candidate it can be effective. Its limits are real: 40 percent nausea at fixed dose, limited male evidence base, MC4R tachyphylaxis with overuse, and contraindications in cardiovascular disease. RxPepsDirect physicians titrate, screen, and adjust protocols with that full picture in mind.
Pharmacy: Optimal Balance, 503A Licensed
Optimal Balance Pharmacy compounds your bremelanotide under a patient-specific prescription, USP <797> sterile standards, and federal 503A oversight. The pharmacy ships the medication directly to you and bills you for the medication.
Medical Service: RxPepsDirect Physicians
A licensed physician reviews your history, screens for cardiovascular contraindications, designs your titration protocol, and writes your prescription. RxPepsDirect bills the $39 medical visit fee for this service.
Transparent Safety Communication
The guide above flags the 40 percent nausea rate, the male evidence gap, MC4R tachyphylaxis, and the BP contraindication. We do not hide limitations to make a sale.
Legal Access in 33 States
Every shipment is a compounded prescription medication filled by a 503A licensed pharmacy under a physician prescription. Bremelanotide has an FDA-approved finished form (Vyleesi) and remains compoundable through the 503A pathway.
References
- Pfaus JG, Sadiq A, Spana C, et al. The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women. CNS Spectr. 2022. PMID: 33455598
- Cipriani S, Alfaroli C, Maseroli E, et al. An evaluation of bremelanotide injection for the treatment of hypoactive sexual desire disorder. Expert Opin Pharmacother. 2023. PMID: 36242769
- Hellstrom WJ. Clinical applications of centrally acting agents in male sexual dysfunction. Int J Impot Res. 2008. PMID: 18552830
- Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019. PMID: 31599840
Related protocol guides
Other protocols in the same clinical territory. Each guide is co-bylined by a licensed RxPepsDirect prescriber.
Continue reading